Persistent hepatitis C can result in life-threatening and severe liver problems, including liver harm, cirrhosis, liver failure or liver cancer. Though many people who have hepatitis C might not experience symptoms, others may have symptoms such as for example fatigue, fever, jaundice and abdominal pain. For more information on hepatitis, please browse the AGA brochure Understanding Hepatitis. .. Adding danoprevir to treatment program for hepatitis C patients leads to high rates of remission The addition of danoprevir to the present treatment regimen for patients with hepatitis C network marketing leads to high rates of remission, according to a fresh article in Gastroenterology, the official journal of the American Gastroenterological Association.Prior adjuvant ADT was allowed if the length of therapy was two years or much less and progression had occurred a lot more than 12 a few months after completion of therapy. Patients who were getting ADT for metastatic disease had been eligible if there is no proof progression and treatment got commenced within 120 days before randomization. Organ function that was sufficient for docetaxel treatment was required . All sufferers provided written informed consent relative to institutional and federal guidelines. TREATMENT SOLUTION, Stratification, and Randomization Individuals were randomly assigned to ADT alone or even to combination therapy with ADT in addition docetaxel at a dose of 75 mg per square meter of body-surface region given every 3 weeks for 6 cycles, with premedication with 8 mg of oral dexamethasone in 12 hours, 3 hours, and one hour before docetaxel infusion.